Search

Displaying results 921 - 930 of 9313 in total
  1. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's … [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named

    Synonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrileCategories: Antivirals used in combination for the treatment of HIV infections
  2. Drug

    Citric acid

    go.drugbank.com/drugs/DB04272
    ApprovedInvestigationalNutraceuticalVet approved

    The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. … Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.

    Mixtures: E-Z-gas II, Sal de Uvas PicotProducts: bdr Re-action natural low base skin refiner exfoliation essence
  3. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    debated due to ethical concerns related to abortion (Rosato et al, 2016). … Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the

    Categories: Sex Hormones and Modulators of the Genital SystemProducts: ACETATO DE ULIPRISTAL
  4. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

  5. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Felodipine

    go.drugbank.com/drugs/DB01023
    Approved

    In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent … Felodipine is used to treat mild to moderate essential hypertension.

  7. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. … By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease.

  8. Drug

    Amitriptyline

    go.drugbank.com/drugs/DB00321
    ApprovedInvestigational

    [A259342] Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.[A174661] … Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    Pivhydrazine, also known as pivazide, is a member of the hydrazine family with irreversible and non-selective inhibitory activity against monoamine oxidases.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. … Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome